Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc.'s Q·Score is 5.9/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: 21% of analysts rate it Sell or Strong Sell. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for SRPT is $22.00, based on ratings from 23 Wall Street analysts. This is 26.0% above the current price of $17.45. Price targets are forward-looking estimates and not guarantees of future performance.

Sarepta Therapeutics, Inc. (SRPT) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 6.4×. The consensus analyst price target of $22.00 is 26% above the current price.

Sarepta Therapeutics, Inc.'s next earnings report is expected on approximately August 5, 2026.

Sarepta Therapeutics, Inc. has a net profit margin of 3.0%, which is positive but relatively thin. Its gross margin stands at 21.6%, reflecting a more cost-intensive business model.

Sarepta Therapeutics, Inc. is reporting revenue declining 1.9% year-over-year.

Sarepta Therapeutics, Inc. has a debt-to-equity ratio of 0.70×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 4.63×, indicating comfortable short-term liquidity.